Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (Nasdaq: PBYI) is a biopharmaceutical company that develops and commercializes cancer therapies. Its commercial product, NERLYNX (neratinib), is an oral medicine approved in the United States for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based therapy… From the company’s description.
Over the twelve months to Jun 30, 2026, Puma Biotechnology, Inc. reported revenue of $231.24M, down 2.9% from a year earlier, and net income of $26.72M. Its operating margin was 13.2%, and operations generated $41.15M in cash. In fiscal 2025, it reported revenue of $228.37M, down 0.9% from fiscal 2024, and net income of $31.11M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Puma Biotechnology, Inc. does
In the company’s own words
Puma Biotechnology, Inc. (Nasdaq: PBYI) is a biopharmaceutical company that develops and commercializes cancer therapies. Its commercial product, NERLYNX (neratinib), is an oral medicine approved in the United States for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based therapy and for advanced or metastatic HER2-positive breast cancer in combination with capecitabine after prior anti-HER2 regimens. The company sells NERLYNX in the United States through a direct specialty sales force and relies on sublicensees to pursue approvals and commercialize it in international markets. Puma also holds worldwide development and commercialization rights to alisertib, an investigational Aurora Kinase A inhibitor, and is pursuing clinical development in small cell lung cancer and hormone receptor-positive breast cancer. The company operates as a single business focused on cancer drug development and commercialization, with NERLYNX as its marketed product and alisertib in its development pipeline. Its website is www.pumabiotechnology.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LOS ANGELES, CA
- Fiscal year end
- December
- CIK
- 1401667
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Puma Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Puma Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Puma Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Puma Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Puma Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”